We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.
Science
Leveraging cutting-edge science and technology to identify and propel best-in-class biologics to the clinic.
Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.
Pipeline
Fueling a pipeline of best-in-class therapies for a range of diseases.
Our business model centers on bringing therapies to patients as rapidly as possible—once a program or set of programs achieves significant progress, we enable their advancement to the clinic by launching spinout companies, engaging in partnerships with other biopharma companies, or continuing to shape their development in-house at Paragon. Our product pipeline demonstrates our progress, with the leading program on track to enter clinical trials in 2023—less than two years from its ideation.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR004 (APG777)
PR001 (APG808)
PR007 (APG990)
PR012 (APG222)
Rights/Partner
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR011 (SPY001)
PR010 (SPY002)
PR014 (SPY003)
PR015 (SPY004)
PR026 (SPY130)
PR022 (SPY120)
PR025 (SPY230)
Rights/Partner
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR002
PR013
Rights/Partner
Undisclosed
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR003
PR016
Rights/Partner
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
ADDITIONAL PIPELINE PROGRAMS
Team
Dedicated experts with a passion for improving health outcomes.
Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Our collaboration with FairJourney Biologics expands the reach and capabilities of our team through dedicated antibody discovery experts and resources. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.
Evan Thompson, Ph.D.
CHIEF OPERATING OFFICER
View BioHussam Shaheen, Ph.D.
SENIOR VICE PRESIDENT OF BIOTHERAPEUTICS
View BioJason Oh, Ph.D.
VICE PRESIDENT OF BIOLOGY
View BioShawn Russell, Ph.D.
VICE PRESIDENT OF CMC
View BioNeta Batscha
VICE PRESIDENT OF CORPORATE STRATEGY & OPERATIONS
View BioDaniel Greenberg
Vice President of Corporate Strategy
View BioYuqi Liu, Ph.D.
DIRECTOR OF PROTEIN SCIENCE
View BioEric Zhu, Ph.D.
DIRECTOR OF BIOTHERAPEUTICS DISCOVERY
View BioByron Kwan, Ph.D.
DIRECTOR OF BIOTHERAPEUTICS
View BioDaniel Rios, Ph.D.
DIRECTOR OF BIOLOGY
View BioRita Vaz, Ph.D.
DIRECTOR OF PROGRAM AND ALLIANCE MANAGEMENT
View BioM. Murshid Alam, Ph.D.
PRINCIPAL SCIENTIST
View BioJake Milligan, Ph.D.
PRINCIPAL SCIENTIST
View BioByong Ha Kang, Ph.D.
SENIOR SCIENTIST
View BioSoraia Oliveira, Ph.D.
Project Manager for Antibody Discovery and Development
View BioJoana Ministro, Ph.D.
PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT
View BioKatie Kelley
CONTROLLER
View BioJames Nzukie
DIRECTOR OF FINANCE PLANNING & ANALYSIS
View BioSophia Medina
ADMINISTRATIVE ASSISTANT
View Bio
About Us
Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, as well as our partnership with FairJourney Biologics, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies and works closely with the Paragon team to provide research and strategic direction.
News
The latest Paragon news and developments.
12.07.2022
Paragon Therapeutics Launches First Spinout, Apogee Therapeutics, to Advance Novel Therapies for Inflammatory and Immunological Conditions
07.20.2021
Paragon Therapeutics Announces Antibody Discovery Joint Venture with FairJourney Biologics
Join Us
Be a part of our innovative team.
We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.